Literature DB >> 10630679

Overexpression of glutathione S-transferase pi enhances the adduct formation of cisplatin with glutathione in human cancer cells.

S Goto1, T Iida, S Cho, M Oka, S Kohno, T Kondo.   

Abstract

In this paper, we provide direct evidence that glutathione S-transferase pi (GSTpi) detoxifies cisplatin (CDDP). We used human colonic cancer HCT8 cells sensitive and resistant to CDDP, the level of cisplatin-glutathione adduct (DDP-GSH) being higher in the resistant cells. There was an overexpression of GSTpi mRNA in these CDDP-resistant cells. Incubation of the cells with CDDP resulted in the formation of DDP-GSH dependent on the CDDP concentration and the incubation time. The formation of DDP-GSH was abolished when the cells were pre-treated with ethacrynic acid or ketoprofen, inhibitors of GSTpi. Purified GSTpi also catalyzed the formation of DDP-GSH in vitro, with an apparent Km of 0.23 mM for CDDP and an apparent Vmax of 4.9 nmol/min/mg protein. The increase in DDP-GSH produced by GSTpi was linear with incubation time up to 3 h and optimal of pH 7.4. A GSTpi transfectant cell line was constructed in HCT8 cells using a pcDNA3.1 (-)/Myc-His B with an expression vector containing cDNA for GSTpi. Transfection of GSTpi cDNA into HCT8 cells resulted in an increase in the expression of GSTpi by 1.4-fold in parallel with an augmentation of the formation of DDP-GSH. These results suggest that GSTpi plays a role in the formation of DDP-GSH and the acquisition of resistance to CDDP in cancer cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10630679     DOI: 10.1080/10715769900301121

Source DB:  PubMed          Journal:  Free Radic Res        ISSN: 1029-2470


  44 in total

1.  Biomarker analysis in patients with advanced gastric cancer treated with S-1 plus cisplatin chemotherapy: orotate phosphoribosyltransferase expression is associated with treatment outcomes.

Authors:  In Sil Choi; Hye Seung Lee; Keun-Wook Lee; Haeryoung Kim; Ki Hwan Kim; Yu Jung Kim; Jee Hyun Kim; Woo Ho Kim; Jong Seok Lee
Journal:  Med Oncol       Date:  2010-06-09       Impact factor: 3.064

2.  Influences of ERCC1, ERCC2, XRCC1, GSTP1, GSTT1, and MTHFR polymorphisms on clinical outcomes in gastric cancer patients treated with EOF chemotherapy.

Authors:  Rujiao Liu; Xiaoying Zhao; Xin Liu; Zhiyu Chen; Lixin Qiu; Ruixuan Geng; Weijian Guo; Guang He; Jiliang Yin; Jin Li; Xiaodong Zhu
Journal:  Tumour Biol       Date:  2015-08-28

3.  Glutathione s-transferase p1: gene sequence variation and functional genomic studies.

Authors:  Ann M Moyer; Oreste E Salavaggione; Tse-Yu Wu; Irene Moon; Bruce W Eckloff; Michelle A T Hildebrandt; Daniel J Schaid; Eric D Wieben; Richard M Weinshilboum
Journal:  Cancer Res       Date:  2008-06-15       Impact factor: 12.701

4.  Combined Gene Expression and RNAi Screening to Identify Alkylation Damage Survival Pathways from Fly to Human.

Authors:  Alfeu Zanotto-Filho; Ravi Dashnamoorthy; Eva Loranc; Luis H T de Souza; José C F Moreira; Uthra Suresh; Yidong Chen; Alexander J R Bishop
Journal:  PLoS One       Date:  2016-04-21       Impact factor: 3.240

5.  Glutathione S-transferase M1 and T1 polymorphisms may predict adverse effects after therapy in children with medulloblastoma.

Authors:  Nadia Barahmani; Sarah Carpentieri; Xio-Nan Li; Tao Wang; Yumei Cao; Laura Howe; Lindsay Kilburn; Murali Chintagumpala; Ching Lau; M Fatih Okcu
Journal:  Neuro Oncol       Date:  2008-10-24       Impact factor: 12.300

6.  Role of glutathione S-transferase P1-1 in the cellular detoxification of cisplatin.

Authors:  Christina Peklak-Scott; Pamela K Smitherman; Alan J Townsend; Charles S Morrow
Journal:  Mol Cancer Ther       Date:  2008-10       Impact factor: 6.261

7.  Glutathione-Scavenging Poly(disulfide amide) Nanoparticles for the Effective Delivery of Pt(IV) Prodrugs and Reversal of Cisplatin Resistance.

Authors:  Xiang Ling; Xing Chen; Imogen A Riddell; Wei Tao; Junqing Wang; Geoffrey Hollett; Stephen J Lippard; Omid C Farokhzad; Jinjun Shi; Jun Wu
Journal:  Nano Lett       Date:  2018-06-19       Impact factor: 11.189

Review 8.  Pharmacogenomics of platinum-based chemotherapy in NSCLC.

Authors:  Michelle A T Hildebrandt; Jian Gu; Xifeng Wu
Journal:  Expert Opin Drug Metab Toxicol       Date:  2009-07       Impact factor: 4.481

9.  MRP2 and GSTP1 polymorphisms and chemotherapy response in advanced non-small cell lung cancer.

Authors:  Ning Sun; Xinchen Sun; Baoan Chen; Hongyan Cheng; Jifeng Feng; Lu Cheng; Zuhong Lu
Journal:  Cancer Chemother Pharmacol       Date:  2009-07-01       Impact factor: 3.333

10.  Genetic polymorphism of GSTP1: prediction of clinical outcome to oxaliplatin/5-FU-based chemotherapy in advanced gastric cancer.

Authors:  Qing-Fang Li; Ru-Yong Yao; Ke-wei Liu; Hong-Ying Lv; Tao Jiang; Jun Liang
Journal:  J Korean Med Sci       Date:  2010-05-24       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.